These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24184119)

  • 21. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.
    Leyh-Bannurah SR; Abou-Haidar H; Dell'Oglio P; Schiffmann J; Tian Z; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
    BJU Int; 2017 May; 119(5):692-699. PubMed ID: 27367469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnetic resonance imaging does not improve the prediction of misclassification of prostate cancer patients eligible for active surveillance when the most stringent selection criteria are based on the saturation biopsy scheme.
    Ploussard G; Xylinas E; Durand X; Ouzaïd I; Allory Y; Bouanane M; Abbou CC; Salomon L; de la Taille A
    BJU Int; 2011 Aug; 108(4):513-7. PubMed ID: 21176083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of predictors of unfavorable pathological features in men eligible for active surveillance using radical prostatectomy specimens: a multi-institutional study.
    Mizuno K; Inoue T; Kinoshita H; Yano T; Kawanishi H; Kanda H; Terada N; Kobayashi T; Kamba T; Mikami Y; Shiraishi T; Uemura Y; Imai Y; Honjo G; Shirase T; Okumura K; Kawakita M; Ogura K; Sugimura Y; Matsuda T; Ogawa O
    Jpn J Clin Oncol; 2016 Dec; 46(12):1156-1161. PubMed ID: 27744325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
    Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
    Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study.
    Beauval JB; Ploussard G; Soulié M; Pfister C; Van Agt S; Vincendeau S; Larue S; Rigaud J; Gaschignard N; Rouprêt M; Drouin S; Peyromaure M; Long JA; Iborra F; Vallancien G; Rozet F; Salomon L;
    Urology; 2012 Sep; 80(3):656-60. PubMed ID: 22770616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer.
    Song C; Kang T; Yoo S; Jeong IG; Ro JY; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Feb; 31(2):168-74. PubMed ID: 21719325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy.
    Pierorazio PM; Lin BM; Mullins JK; Hyndman ME; Schaeffer EM; Han M; Partin AW; Pavlovich CP
    Urol Oncol; 2013 Jul; 31(5):589-94. PubMed ID: 21664838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance.
    Ploussard G; de la Taille A; Terry S; Allory Y; Ouzaïd I; Vacherot F; Abbou CC; Salomon L
    Urol Oncol; 2013 Oct; 31(7):1060-6. PubMed ID: 22300755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer.
    Ritch CR; You C; May AT; Herrell SD; Clark PE; Penson DF; Chang SS; Cookson MS; Smith JA; Barocas DA
    Urology; 2014 Jun; 83(6):1309-15. PubMed ID: 24746665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y; Loblaw A; Klotz L
    J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance.
    Ploussard G; de la Taille A; Bayoud Y; Durand X; Terry S; Xylinas E; Allory Y; Vacherot F; Abbou CC; Salomon L
    Eur Urol; 2012 Feb; 61(2):356-62. PubMed ID: 21803484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
    Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients.
    Suardi N; Gallina A; Capitanio U; Salonia A; Lughezzani G; Freschi M; Mottrie A; Rigatti P; Montorsi F; Briganti A
    Cancer; 2012 Feb; 118(4):973-80. PubMed ID: 21751185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
    Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
    J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.